LILRB1 and Miyoshi myopathy: The sensitivity of MM cells to RSL3 following knockdown of these proteins highlights the potential of LILRB1 and SREBPs and the cholesterol biosynthesis pathway as therapeutic targets for MM [47, 73, 95].